Efficacy and Safety of Neoadjuvant Trastuzumab, Pyrotinib, and Dalpiciclib Without Chemotherapy in Early-Stage HR-negative/HER2-positive Breast Cancer: an Open-Label, Single-Arm Phase II Trial.
Journal of Clinical Oncology（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要